Boundless Bio Initiates BBI-940 Clinical Trial
"With the KOMODO-1 trial of BBI-940 actively enrolling, we are excited to evaluate this potentially first-in-class oral Kinesin degrader in patients with breast cancer who are seeking new treatment options. BBI-940 is designed to disrupt ecDNA segregation and inheritance, a differentiated mechanism for targeting chromosomally unstable cancers. The Boundless team is focused on clinical execution and reaching an initial proof-of-concept readout within our existing cash runway," said Zachary Hornby, President and Chief Executive Officer of Boundless Bio.
Trade with 70% Backtested Accuracy
Analyst Views on BOLD
About BOLD
About the author
Boundless Bio Q4 Earnings Miss Expectations
- Earnings Performance: Boundless Bio reported a Q4 GAAP EPS of -$0.58, missing expectations by $0.12, indicating challenges in profitability that could undermine investor confidence.
- Cash Reserves: As of December 31, 2025, the company had $107.6 million in cash, cash equivalents, and short-term investments, reflecting a solid liquidity position in the short term, though long-term sustainability remains a concern.
- Operational Funding Outlook: The company expects its cash reserves to fund operations into the second half of 2028, coinciding with the anticipated initial clinical proof-of-concept readout from KOMODO-1, which is crucial for future growth prospects.
- Market Reaction Expectations: Given the earnings miss, investors may express concerns regarding the company's future clinical trials and cash utilization plans, potentially impacting stock performance and market confidence.
Analysis of Growth Drivers in the Biliary Tract Cancer Market
- Market Size Growth: The biliary tract cancer market is projected to reach $1.1 billion in 2024, with the U.S. accounting for approximately 60% of this market, indicating a strong demand for new therapies in this leading region.
- Emerging Drug Launches: The introduction of new drugs such as Tinengotinib and Rilvegostomig is expected to further drive market growth, particularly in the areas of targeted therapies and immuno-oncology, enhancing treatment options for patients.
- Advancements in Diagnostic Technology: Improvements in imaging techniques like MRI, endoscopic ultrasound, and PET have enhanced the accuracy of biliary tract cancer diagnoses, enabling earlier detection and personalized treatment approaches, thereby improving patient outcomes.
- Market Dynamics in Treatment: By 2034, chemotherapy is expected to remain the primary revenue source for biliary tract cancer treatment, and the introduction of new therapies will alter the competitive landscape, fostering medical innovation and economic growth.
Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
POTENTIATE Trial Enrollment: Boundless Bio has opened enrollment for the BBI-355 and BBI-825 combination arm of the POTENTIATE trial, expecting to deliver initial proof-of-concept clinical data within its cash runway timeline.
Financial Overview: The company reported a net loss of $15.7 million for Q2 2025, with $127 million in cash supporting operations through expected clinical readouts into 2028.
Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board
Appointment of Carolyn Ng: Carolyn Ng has been appointed to the external advisory board of the Rice Biotech Launch Pad, bringing her extensive experience in biotech and company building to support the accelerator's mission of translating health and medical technology discoveries into effective therapies.
Role of the Rice Biotech Launch Pad: The Rice Biotech Launch Pad aims to expedite the transition of innovative research from Rice University into clinical studies and commercialization, contributing to Houston's growth as a leading biotech hub.
Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Company Announcement: Boundless Bio, a clinical-stage oncology company, will have its CEO Zachary Hornby participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, in Miami, FL.
Research Focus: The company is dedicated to developing therapies targeting extrachromosomal DNA (ecDNA) in oncogene amplified cancers, with ongoing clinical trials for their therapeutic candidates BBI-355 and BBI-825.
Leerink Partners Downgrades Boundless Bio to Market Perform, Lowers Price Target to $3
Real-time Trading Intelligence: Benzinga Pro offers the fastest and most accurate stock market news alerts to help traders succeed in their investments.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights generated by Benzinga reporters.
Boundless Bio Q4 Earnings Miss Expectations
- Earnings Performance: Boundless Bio reported a Q4 GAAP EPS of -$0.58, missing expectations by $0.12, indicating challenges in profitability that could undermine investor confidence.
- Cash Reserves: As of December 31, 2025, the company had $107.6 million in cash, cash equivalents, and short-term investments, reflecting a solid liquidity position in the short term, though long-term sustainability remains a concern.
- Operational Funding Outlook: The company expects its cash reserves to fund operations into the second half of 2028, coinciding with the anticipated initial clinical proof-of-concept readout from KOMODO-1, which is crucial for future growth prospects.
- Market Reaction Expectations: Given the earnings miss, investors may express concerns regarding the company's future clinical trials and cash utilization plans, potentially impacting stock performance and market confidence.
Analysis of Growth Drivers in the Biliary Tract Cancer Market
- Market Size Growth: The biliary tract cancer market is projected to reach $1.1 billion in 2024, with the U.S. accounting for approximately 60% of this market, indicating a strong demand for new therapies in this leading region.
- Emerging Drug Launches: The introduction of new drugs such as Tinengotinib and Rilvegostomig is expected to further drive market growth, particularly in the areas of targeted therapies and immuno-oncology, enhancing treatment options for patients.
- Advancements in Diagnostic Technology: Improvements in imaging techniques like MRI, endoscopic ultrasound, and PET have enhanced the accuracy of biliary tract cancer diagnoses, enabling earlier detection and personalized treatment approaches, thereby improving patient outcomes.
- Market Dynamics in Treatment: By 2034, chemotherapy is expected to remain the primary revenue source for biliary tract cancer treatment, and the introduction of new therapies will alter the competitive landscape, fostering medical innovation and economic growth.
Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
POTENTIATE Trial Enrollment: Boundless Bio has opened enrollment for the BBI-355 and BBI-825 combination arm of the POTENTIATE trial, expecting to deliver initial proof-of-concept clinical data within its cash runway timeline.
Financial Overview: The company reported a net loss of $15.7 million for Q2 2025, with $127 million in cash supporting operations through expected clinical readouts into 2028.
Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board
Appointment of Carolyn Ng: Carolyn Ng has been appointed to the external advisory board of the Rice Biotech Launch Pad, bringing her extensive experience in biotech and company building to support the accelerator's mission of translating health and medical technology discoveries into effective therapies.
Role of the Rice Biotech Launch Pad: The Rice Biotech Launch Pad aims to expedite the transition of innovative research from Rice University into clinical studies and commercialization, contributing to Houston's growth as a leading biotech hub.
Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Company Announcement: Boundless Bio, a clinical-stage oncology company, will have its CEO Zachary Hornby participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, in Miami, FL.
Research Focus: The company is dedicated to developing therapies targeting extrachromosomal DNA (ecDNA) in oncogene amplified cancers, with ongoing clinical trials for their therapeutic candidates BBI-355 and BBI-825.
Leerink Partners Downgrades Boundless Bio to Market Perform, Lowers Price Target to $3
Real-time Trading Intelligence: Benzinga Pro offers the fastest and most accurate stock market news alerts to help traders succeed in their investments.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights generated by Benzinga reporters.
